| Item | Name | Cat. No. | Tag/Conjugates |
| Anti-APP mAbs [Lecanemab Biosimilar] (MABL-4852) | MABL-4852 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-IL17A&IL17F mAbs [Lecankitug Biosimilar] (MABL-4853) | MABL-4853 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-NT5E/CALJA/CD73;PDCD1/CD279/PD1 mAbs [Ledostomig Biosimilar] (MABL-4854) | MABL-4854 | ELISA, FACS, Functional assay, in vivo binding | G1;na, Kappa;Kappa |
| Anti-NCA90/p95 mAbs [Lemalesomab Biosimilar] (MABL-4855) | MABL-4855 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-IAP/CD47 mAbs [Lemzoparlimab Biosimilar] (MABL-4856) | MABL-4856 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-Hepatitis B Virus mAbs [Lenvervimab Biosimilar] (MABL-4857) | MABL-4857 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-CSF2 mAbs [Lenzilumab Biosimilar] (MABL-4858) | MABL-4858 | ELISA, FACS, Functional assay, in vivo binding | Lenzilumab, Lenzilumab |
| Anti-TfR1/CD71 mAbs [Lepunafusp Biosimilar] (MABL-4859) | MABL-4859 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-TGFB1 mAbs [Lerdelimumab Biosimilar] (MABL-4860) | MABL-4860 | ELISA, FACS, Functional assay, in vivo binding | G4, Lambda |
| Anti-CCR5/CD195 mAbs [Leronlimab Biosimilar] (MABL-4861) | MABL-4861 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-PDL1/CD274 mAbs [Lesabelimab Biosimilar] (MABL-4862) | MABL-4862 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-EGFR/ERBB1/HER1;ERBB3/HER3 mAbs [Izalontamab Biosimilar] (MABL-4831) | MABL-4831 | ELISA, FACS, Functional assay, in vivo binding | G1;na, Kappa;Lambda |
| Anti-C5AR1/CD88 mAbs [Izastobart Biosimilar] (MABL-4832) | MABL-4832 | ELISA, FACS, Functional assay, in vivo binding | G1, Lambda |
| Anti-ADAM9 mAbs [Izeltabart Biosimilar] (MABL-4833) | MABL-4833 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-NGFB (Canine) mAbs [Izenivetmab Biosimilar] (MABL-4834) | MABL-4834 | ELISA, FACS, Functional assay, in vivo binding | G2, Kappa |
| Anti-ICOS/CD278;PDCD1/CD279/PD1 mAbs [Izuralimab Biosimilar] (MABL-4835) | MABL-4835 | ELISA, FACS, Functional assay, in vivo binding | G1;na, Kappa;Kappa |
| Anti-CEACAM5/CD66e mAbs [Labetuzumab Biosimilar] (MABL-4836) | MABL-4836 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-CSF1 mAbs [Lacnotuzumab Biosimilar] (MABL-4837) | MABL-4837 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-KIR3DL2/CD158K mAbs [Lacutamab Biosimilar] (MABL-4838) | MABL-4838 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-SLC39A6/ZIP6 mAbs [Ladiratuzumab Biosimilar] (MABL-4839) | MABL-4839 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
联系我们
Copyright © 2012-2029 西安迈博睿(Mabioway)生物科技有限公司 版权所有
地址:陕西省西安市浐灞生态区广运潭大道南段4555号长安大学科技园4号楼A单元2层
电话:15339069646 邮箱:info@mabioway.cn
